Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis.

Krueger JG, Wharton KA Jr, Schlitt T, Suprun M, Torene RI, Jiang X, Wang CQ, Fuentes-Duculan J, Hartmann N, Peters T, Koroleva I, Hillenbrand R, Letzkus M, Yu X, Li Y, Glueck A, Hasselberg A, Flannery B, Suárez-Fariñas M, Hueber W.

J Allergy Clin Immunol. 2019 May 24. pii: S0091-6749(19)30682-7. doi: 10.1016/j.jaci.2019.04.029. [Epub ahead of print]

2.

Population PK-PD Model for Tolerance Evaluation to the p38 MAP Kinase Inhibitor BCT197.

De Buck S, Hueber W, Vitaliti A, Straube F, Emotte C, Bruin G, Woessner R.

CPT Pharmacometrics Syst Pharmacol. 2015 Dec;4(12):691-700. doi: 10.1002/psp4.12037. Epub 2015 Nov 9.

3.

Association of HLA-DRB1 alleles with clinical responses to the anti-interleukin-17A monoclonal antibody secukinumab in active rheumatoid arthritis.

Burmester GR, Durez P, Shestakova G, Genovese MC, Schulze-Koops H, Li Y, Wang YA, Lewitzky S, Koroleva I, Berneis AA, Lee DM, Hueber W.

Rheumatology (Oxford). 2016 Jan;55(1):49-55. doi: 10.1093/rheumatology/kev258. Epub 2015 Aug 12.

PMID:
26268815
4.

Long-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: an observational study.

Baraliakos X, Borah B, Braun J, Baeten D, Laurent D, Sieper J, Emery P, McInnes IB, van Laar JM, Wordsworth P, Wollenhaupt J, Kellner H, Colin L, Vandenhende F, Radford K, Hueber W.

Ann Rheum Dis. 2016 Feb;75(2):408-12. doi: 10.1136/annrheumdis-2015-207544. Epub 2015 Aug 6.

PMID:
26248638
5.

Evidence that a neutrophil-keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis.

Reich K, Papp KA, Matheson RT, Tu JH, Bissonnette R, Bourcier M, Gratton D, Kunynetz RA, Poulin Y, Rosoph LA, Stingl G, Bauer WM, Salter JM, Falk TM, Blödorn-Schlicht NA, Hueber W, Sommer U, Schumacher MM, Peters T, Kriehuber E, Lee DM, Wieczorek GA, Kolbinger F, Bleul CC.

Exp Dermatol. 2015 Jul;24(7):529-35. doi: 10.1111/exd.12710. Epub 2015 May 8.

6.

Secukinumab for ankylosing spondylitis--authors' reply.

Baeten D, Hueber W.

Lancet. 2014 Mar 1;383(9919):780-1. doi: 10.1016/S0140-6736(14)60399-8. No abstract available.

PMID:
24581662
7.

Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial.

Baeten D, Baraliakos X, Braun J, Sieper J, Emery P, van der Heijde D, McInnes I, van Laar JM, Landewé R, Wordsworth P, Wollenhaupt J, Kellner H, Paramarta J, Wei J, Brachat A, Bek S, Laurent D, Li Y, Wang YA, Bertolino AP, Gsteiger S, Wright AM, Hueber W.

Lancet. 2013 Nov 23;382(9906):1705-13. doi: 10.1016/S0140-6736(13)61134-4. Epub 2013 Sep 13. Erratum in: Lancet. 2014 May 3;383(9928):1548.

PMID:
24035250
8.

Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial.

McInnes IB, Sieper J, Braun J, Emery P, van der Heijde D, Isaacs JD, Dahmen G, Wollenhaupt J, Schulze-Koops H, Kogan J, Ma S, Schumacher MM, Bertolino AP, Hueber W, Tak PP.

Ann Rheum Dis. 2014 Feb;73(2):349-56. doi: 10.1136/annrheumdis-2012-202646. Epub 2013 Jan 29.

PMID:
23361084
9.

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.

Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins PD, Wehkamp J, Feagan BG, Yao MD, Karczewski M, Karczewski J, Pezous N, Bek S, Bruin G, Mellgard B, Berger C, Londei M, Bertolino AP, Tougas G, Travis SP; Secukinumab in Crohn's Disease Study Group.

Gut. 2012 Dec;61(12):1693-700. doi: 10.1136/gutjnl-2011-301668. Epub 2012 May 17.

10.

Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis.

Hueber W, Patel DD, Dryja T, Wright AM, Koroleva I, Bruin G, Antoni C, Draelos Z, Gold MH; Psoriasis Study Group, Durez P, Tak PP, Gomez-Reino JJ; Rheumatoid Arthritis Study Group, Foster CS, Kim RY, Samson CM, Falk NS, Chu DS, Callanan D, Nguyen QD; Uveitis Study Group, Rose K, Haider A, Di Padova F.

Sci Transl Med. 2010 Oct 6;2(52):52ra72. doi: 10.1126/scitranslmed.3001107.

11.

The number of elevated cytokines and chemokines in preclinical seropositive rheumatoid arthritis predicts time to diagnosis in an age-dependent manner.

Deane KD, O'Donnell CI, Hueber W, Majka DS, Lazar AA, Derber LA, Gilliland WR, Edison JD, Norris JM, Robinson WH, Holers VM.

Arthritis Rheum. 2010 Nov;62(11):3161-72. doi: 10.1002/art.27638.

12.

Autoimmunity against fibrinogen mediates inflammatory arthritis in mice.

Ho PP, Lee LY, Zhao X, Tomooka BH, Paniagua RT, Sharpe O, BenBarak MJ, Chandra PE, Hueber W, Steinman L, Robinson WH.

J Immunol. 2010 Jan 1;184(1):379-90. doi: 10.4049/jimmunol.0901639. Epub 2009 Nov 30.

13.

A broad screen for targets of immune complexes decorating arthritic joints highlights deposition of nucleosomes in rheumatoid arthritis.

Monach PA, Hueber W, Kessler B, Tomooka BH, BenBarak M, Simmons BP, Wright J, Thornhill TS, Monestier M, Ploegh H, Robinson WH, Mathis D, Benoist C.

Proc Natl Acad Sci U S A. 2009 Sep 15;106(37):15867-72. doi: 10.1073/pnas.0908032106. Epub 2009 Aug 31.

14.

Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis.

Hueber W, Tomooka BH, Batliwalla F, Li W, Monach PA, Tibshirani RJ, Van Vollenhoven RF, Lampa J, Saito K, Tanaka Y, Genovese MC, Klareskog L, Gregersen PK, Robinson WH.

Arthritis Res Ther. 2009;11(3):R76. doi: 10.1186/ar2706. Epub 2009 May 21.

15.

Genomics and proteomics: Applications in autoimmune diseases.

Hueber W, Robinson WH.

Pharmgenomics Pers Med. 2009;2:39-48. Epub 2009 Aug 17.

16.

Arthritis induced by posttranslationally modified (citrullinated) fibrinogen in DR4-IE transgenic mice.

Hill JA, Bell DA, Brintnell W, Yue D, Wehrli B, Jevnikar AM, Lee DM, Hueber W, Robinson WH, Cairns E.

J Exp Med. 2008 Apr 14;205(4):967-79. doi: 10.1084/jem.20072051. Epub 2008 Apr 7.

17.

AUF1, the regulator of tumor necrosis factor alpha messenger RNA decay, is targeted by autoantibodies of patients with systemic rheumatic diseases.

Skriner K, Hueber W, Süleymanoglu E, Höfler E, Krenn V, Smolen J, Steiner G.

Arthritis Rheum. 2008 Feb;58(2):511-20. doi: 10.1002/art.23306.

18.

Peptide-coated nanotube-based biosensor for the detection of disease-specific autoantibodies in human serum.

Drouvalakis KA, Bangsaruntip S, Hueber W, Kozar LG, Utz PJ, Dai H.

Biosens Bioelectron. 2008 May 15;23(10):1413-21. doi: 10.1016/j.bios.2007.11.022. Epub 2007 Dec 14.

19.

Natural killer cells trigger differentiation of monocytes into dendritic cells.

Zhang AL, Colmenero P, Purath U, Teixeira de Matos C, Hueber W, Klareskog L, Tarner IH, Engleman EG, Söderström K.

Blood. 2007 Oct 1;110(7):2484-93. Epub 2007 Jul 12.

20.

Proteomic analysis of secreted proteins in early rheumatoid arthritis: anti-citrulline autoreactivity is associated with up regulation of proinflammatory cytokines.

Hueber W, Tomooka BH, Zhao X, Kidd BA, Drijfhout JW, Fries JF, van Venrooij WJ, Metzger AL, Genovese MC, Robinson WH.

Ann Rheum Dis. 2007 Jun;66(6):712-9. Epub 2006 Aug 10.

21.

Proteomic biomarkers for autoimmune disease.

Hueber W, Robinson WH.

Proteomics. 2006 Jul;6(14):4100-5. Review.

PMID:
16786488
22.

Antigen microarray profiling of autoantibodies in rheumatoid arthritis.

Hueber W, Kidd BA, Tomooka BH, Lee BJ, Bruce B, Fries JF, Sønderstrup G, Monach P, Drijfhout JW, van Venrooij WJ, Utz PJ, Genovese MC, Robinson WH.

Arthritis Rheum. 2005 Sep;52(9):2645-55.

23.

Interferon-alpha-inducible proteins are novel autoantigens in murine lupus.

Hueber W, Zeng D, Strober S, Utz PJ.

Arthritis Rheum. 2004 Oct;50(10):3239-49.

24.

Characterization of novel antigens recognized by serum autoantibodies from anti-CD1 TCR-transgenic lupus mice.

Hueber W, Zeng D, Sharpe O, Robinson WH, Strober S, Utz PJ.

Eur J Immunol. 2004 Jun;34(6):1654-62.

25.

Autoantibodies in early arthritis: advances in diagnosis and prognostication.

Hueber W, Utz PJ, Robinson WH.

Clin Exp Rheumatol. 2003 Sep-Oct;21(5 Suppl 31):S59-64. Review.

PMID:
14969052
26.

EULAR response criteria for polymyalgia rheumatica: results of an initiative of the European Collaborating Polymyalgia Rheumatica Group (subcommittee of ESCISIT).

Leeb BF, Bird HA, Nesher G, Andel I, Hueber W, Logar D, Montecucco CM, Rovensky J, Sautner J, Sonnenblick M.

Ann Rheum Dis. 2003 Dec;62(12):1189-94.

27.

Autoantibody profiling for the study and treatment of autoimmune disease.

Hueber W, Utz PJ, Steinman L, Robinson WH.

Arthritis Res. 2002;4(5):290-5. Epub 2002 May 7. Review.

28.

Autoantigen microarrays for multiplex characterization of autoantibody responses.

Robinson WH, DiGennaro C, Hueber W, Haab BB, Kamachi M, Dean EJ, Fournel S, Fong D, Genovese MC, de Vegvar HE, Skriner K, Hirschberg DL, Morris RI, Muller S, Pruijn GJ, van Venrooij WJ, Smolen JS, Brown PO, Steinman L, Utz PJ.

Nat Med. 2002 Mar;8(3):295-301.

PMID:
11875502
29.

Reply

Hueber W, Hassfeld W, Smolen JS, Steiner G.

Rheumatology (Oxford). 2000 Feb;39(2):218. No abstract available.

PMID:
10725081
30.

Sensitivity and specificity of anti-Sa autoantibodies for rheumatoid arthritis.

Hueber W, Hassfeld W, Smolen JS, Steiner G.

Rheumatology (Oxford). 1999 Feb;38(2):155-9.

PMID:
10342629
31.

Chronic lower back pain due to sarcoma.

Hueber W, Dominkus M, Vesely M, Mendel M, Kotz R, Czembirek H, Smolen JS.

Clin Exp Rheumatol. 1998 May-Jun;16(3):309-12.

PMID:
9631756

Supplemental Content

Loading ...
Support Center